Excellos, Lonza, and Akadeum Life Sciences have joined forces in a pioneering initiative to revolutionize cell therapy manufacturing standards by enhancing the quality of starting materials. This innovative project aims to redefine the landscape of cell therapy manufacturing by focusing on the critical role of starting material quality. By combining expertise in donor cell characterization, automated manufacturing, and cell separation technology, the collaboration seeks to optimize workflows and enhance outcomes in the field of cell and gene therapy (CGT).
The project emphasizes the importance of integrated platforms that span from donor sourcing to manufacturing processes. Excellos brings its comprehensive donor-to-dose capabilities, including donor management, apheresis, cell characterization, and GMP manufacturing. Akadeum contributes its gentle flotation-based cell separation technology, while Lonza offers its Cocoon® Platform, an automated manufacturing system that facilitates decentralized scale-up.
While the companies are exploring the technical feasibility of integrating these diverse approaches into a modular workflow, the immediate priority is to exchange best practices and foster aligned innovation strategies through industry events. Notable upcoming events include a symposium on August 12 at Excellos’ San Diego headquarters and a webinar on August 21 titled “Unlocking Upstream Value: Donor-to-Dose Solutions for Scalable Cell Therapy Manufacturing.”
The August 12 symposium will feature expert panels discussing topics such as supply chain risk, regulatory advancements, and the role of AI and machine learning in CGT operations. On August 21, the webinar will bring together scientific experts from the three organizations to delve into how upstream decisions related to donor sourcing, apheresis processing, cell selection, and automated manufacturing influence therapeutic performance, reduce variability, and enhance scale-up for both autologous and allogeneic therapies.
The collaborative effort is underpinned by a shared conviction that superior starting materials lead to superior therapies. By combining deeply characterized donor materials, gentle cell selection techniques, and closed-system manufacturing processes, the companies aim to lay the groundwork for scalable and consistent therapies. The integration of Akadeum’s microbubble technology within an automated environment like the Cocoon® Platform is seen as a crucial step towards scaling up without compromising cell quality.
Lonza’s commitment to the collaboration underscores the significance of integrating technologies to reduce variability and expedite therapeutic timelines. The collective vision is to explore opportunities for technical integration and data-sharing to advance the field of cell therapy manufacturing. The companies are dedicated to investigating how these technologies can harmonize to support industry-wide progress in the development of cell and gene therapies.
Key Takeaways:
– Collaboration between Excellos, Lonza, and Akadeum aims to enhance cell therapy manufacturing through improved starting material quality and integrated technologies.
– The focus is on emphasizing the impact of upstream quality on downstream performance and clinical consistency in cell and gene therapy.
– The shared belief that quality starting materials are foundational for superior therapies is a driving force behind the collaborative efforts.
– The companies plan to explore further technical integration and data-sharing to advance the overall quality and efficiency of cell therapy manufacturing processes.
Read more on finance.yahoo.com